Publications by authors named "Nadine Besson"

Claim this Profile
B
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Anna G Turkina, Tamas Masszi, Nadine Besson

Am J Hematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H Jean Khoury, Tim H Brümmendorf, Nadine Besson

Blood· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
Peter C Trask, David Cella, Nadine Besson, Virginia Kelly, Tamás Masszi

Leuk Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
H Jean Khoury, Jorge E Cortes, Hagop M Kantarjian, Carlo Gambacorti-Passerini, Michele Baccarani, Nadine Besson

Blood· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Jorge E Cortes, Hagop M Kantarjian, Tim H Brümmendorf, Dong-Wook Kim, Anna G Turkina, Nadine Besson

Blood· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis